Corbus Pharmaceuticals Holdings (CRBP) Short term Debt (2021 - 2024)

Corbus Pharmaceuticals Holdings' Short term Debt history runs 4 years deep, the most recent figure standing at $12.8 million for Q1 2024.

• On a quarterly basis, Short term Debt rose 154.85% year-over-year to $12.8 million in Q1 2024; TTM through Mar 2024 was $12.8 million, a 154.85% increase from a year earlier, with the FY2023 full-year figure at $15.9 million, up 469.03% from the prior year.
• Short term Debt slipped to $12.8 million in Q1 2024 per CRBP's latest filing, from $15.9 million in the prior quarter.
• Across five years, Short term Debt topped out at $17.8 million in Q3 2023 and bottomed at $2.8 million in Q4 2022.
• The 4-year median for Short term Debt is $7.2 million (2022), against an average of $8.7 million.
• Across the five-year window, Short term Debt retreated 9.62% in 2022 and surged 469.03% in 2023, its largest moves.
• Year by year, Short term Debt stood at $3.1 million in 2021, then decreased by 9.62% to $2.8 million in 2022, then jumped by 469.03% to $15.9 million in 2023, then decreased by 19.76% to $12.8 million in 2024.
• Per Business Quant, the three latest CRBP Short term Debt figures stand at $12.8 million (Q1 2024), $15.9 million (Q4 2023), and $17.8 million (Q3 2023).